•

Tampa Bay Medical and Research District · Tampa, FL

Investor Relations

A de-risked path into human
oncology

Company and investor-relations information. This page is informational and is not an offer to sell securities.

Our History

More than 100 combined years of research produced a series of patents that LifePulse™ Corporation acquired in 2020, as Pulsed Electrical Fields became one of the most important technologies in biotech. LifePulse™ was founded by Gary Strange in 2018.

Our Mission

To make this technology available in the United States first, then worldwide — beginning with pancreatic tumor trials in human medicine.

Our Patents

$37M of non-dilutive research grants from the NIH, NCI and others have produced our growing list of patents that are the foundation of the IntelliPulse™ platform.

About LifePulse™ Corporation

US engineered and manufactured, from research bench to clinical practice

Bob Roda

Chief Executive Officer

Extensive experience and a proven record of success leading teams and building businesses across MedTech, Diagnostics, and Pharmaceuticals.

 

Dr. Chris Slachta, Ph.D., M.B.A.

Chief Operating Officer

Combines scientific rigor with operational excellence, driving growth across the healthcare spectrum.

 

Bill Gilmour

Chief Financial Officer

Seasoned finance executive with extensive operating and M&A experience driving financial strategy and growth.

 

Gary Strange

Sr. Vice President, Business Development

Founder of LifePulse™ Corporation with 30+ years of business leadership, now leading the Animal Health division.

 
 

Dr. Paula de Marval

Senior Director of Research

Highly motivated scientific director with deep knowledge in cancer biology and oncology drug discovery.

Scientific & Regulatory Advisory Board

Chelsea Tripp, DVM, ACVIM (Oncology)

Recognized veterinary-technology expert and key opinion leader.

Alexander Fleming, MD

Founder of Kinexum, an FDA translational-guidance firm.

Dr. C Richard Piazza

Executive Chairman

Former CEO of Vital Therapies (NASDAQ: VTL); led the successful divestiture of SoloPak Pharmaceuticals to Smith & Nephew.

Gary Strange

Sr. Vice President, Business Development

Founder of LifePulse™ Corporation with 30+ years of business leadership, now leading the Animal Health division.

Donald G. Fell

Director

Sits on four NASDAQ-listed boards, bringing deep business acumen to LifePulse™ Corporation.

Dr. Gerald Sokol, MD

Director

Practicing physician boarded in radiation oncology, internal medicine, and medical oncology, with decades of clinical trial experience and board leadership.

Bob Roda

Director

Highly skilled leader with deep experience across public and private companies.

Greg Walters

Director

Former securities attorney and serial entrepreneur, including a med-device launch through FDA approval.

Trinity Bui

Director

39 years in finance and investment; founder of TFIC; holds an MBA in Finance.

GRANT AWARDS

Competitively awarded, non-dilutive funding

NATIONAL INSTITUTES OF HEALTH

$225,000

STTR Award

Awarded May 2023

NATIONAL INSTITUTES OF HEALTH

$2M

SBIR Direct to Phase II

Awarded September 2025

Open roles — coming soon

We are not actively posting roles right now, but we always want to hear from strong candidates.

Submit your resume

De-risked path

Veterinary traction funds and validates entry into human oncology.

Proven technology

Combined revenue of nearly $1M since launch, with the platform in clinical use across US veterinary centers.

IP position

Both US and PCT patents, providing a solid wall of protection for years to come.

Clear direction

Defined roadmap through 510(k) clearance and acquisition readiness.

Market opportunity

Veterinary Oncology TAM

$0B

165M pets in the United States; 1 in 4 dogs develop cancer.

Human Oncology TAM

$0B

Melanoma is the initial target indication.

Financial trajectory

SINCE 2024 LAUNCH

Nearly $1M

Combined revenue across US veterinary centers since commercial launch.

2027–29 PROJECTION

$15M+ by 2028

510(k) clearance and acquisition readiness.

Strategic roadmap 2026–2029

2026

Foundation & Scale

Expand the veterinary installed base and scale commercial operations.

2027

FDA 510(k) Clearance

Pursue clearance with breakthrough designation strategy.

2028–29

Partnership and Exit

Strategic partnership and acquisition readiness.

IP snapshot

20

Issued patents

2

Pending

15+ yrs

Global protection

2

Patent families (human / vet)

Trademarks: IntelliPulse™ and LifePulse™.